Ignite Creation Date:
2025-12-26 @ 10:56 AM
Ignite Modification Date:
2025-12-29 @ 12:25 PM
Study NCT ID:
NCT01274208
Status:
UNKNOWN
Last Update Posted:
2014-11-19
First Post:
2011-01-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005776', 'term': 'Gaucher Disease'}, {'id': 'D006526', 'term': 'Hepatitis C'}], 'ancestors': [{'id': 'D013106', 'term': 'Sphingolipidoses'}, {'id': 'D020140', 'term': 'Lysosomal Storage Diseases, Nervous System'}, {'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008064', 'term': 'Lipidoses'}, {'id': 'D008052', 'term': 'Lipid Metabolism, Inborn Errors'}, {'id': 'D016464', 'term': 'Lysosomal Storage Diseases'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 80}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2011-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-11', 'completionDateStruct': {'date': '2016-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-11-18', 'studyFirstSubmitDate': '2011-01-10', 'studyFirstSubmitQcDate': '2011-01-10', 'lastUpdatePostDateStruct': {'date': '2014-11-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-01-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Gaucher patients' immune system provide enhanced immunity against hepatitis c virus", 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'the role Glucocerebroside level have by enhanced immunity in patients with Gaucher disease', 'timeFrame': '30 days'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Gaucher disease, Hepatitis C , Glucocerebroside immunity'], 'conditions': ['Gaucher Disease', 'Hepatitis C']}, 'referencesModule': {'references': [{'pmid': '11498237', 'type': 'BACKGROUND', 'citation': "Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Gaucher's disease. Lancet. 2001 Jul 28;358(9278):324-7. doi: 10.1016/S0140-6736(01)05490-3. No abstract available."}, {'pmid': '17644022', 'type': 'BACKGROUND', 'citation': 'Butters TD. Gaucher disease. Curr Opin Chem Biol. 2007 Aug;11(4):412-8. doi: 10.1016/j.cbpa.2007.05.035. Epub 2007 Jul 23.'}, {'pmid': '16720474', 'type': 'BACKGROUND', 'citation': 'Beutler E. Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl. 2006 Apr;95(451):103-9. doi: 10.1111/j.1651-2227.2006.tb02398.x.'}, {'pmid': '15208782', 'type': 'BACKGROUND', 'citation': 'Slatkin M. A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am J Hum Genet. 2004 Aug;75(2):282-93. doi: 10.1086/423146. Epub 2004 Jun 18.'}, {'pmid': '8516282', 'type': 'BACKGROUND', 'citation': 'Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5384-90. doi: 10.1073/pnas.90.12.5384.'}, {'type': 'RESULT', 'citation': 'Zigmond E LG, Pappo O, Zangen S, Levy Sklair M, Hemed N, Rabbani E, Itamar R, Ilan Y, Margalit M. Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: A phase I/II clinical study. Hepatology 2006;44 .180A, .'}]}, 'descriptionModule': {'briefSummary': 'Study objectives:\n\n* Investigate the anti-HCV response in patients with Gaucher disease(GD)\n* Define the potential role of high levels of Glucocerebroside in the immune system\n\nStudy hypothesis:\n\nHigh levels of Glucocerebroside can be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells', 'detailedDescription': 'Gaucher disease is the most common glycolipid storage disorder, caused by reduced activity of the lysosomal enzyme glucocerebrosidase, which leads to the accumulation of the substrate, glucocerebroside (GC), in the cells of the reticulo-endothelial system.\n\nOne of the hallmarks of GD is its great phenotypic heterogeneity with variable presentations and symptoms, beginning with a lethal variant of infants dying at or near birth with hydrops fetalis and ichthyoids at one extreme and totally asymptomatic individuals without any physical or laboratory abnormalities at the other extreme.\n\nThis autosomal recessive disease is pan-ethnic, but it is especially prevalent among Ashkenazi Jews. From over 300 different mutations reported in the glucocerebrosidase gene, five account for 98% of the disease-producing alleles. Of these mutations, N370S (or 1226G) occurs in 1 out of 17 Ashkenazi individuals, leading to a disease frequency of 1:850 in this ethnic group.\n\nThe high prevalence of more than a single mutation among Ashkenazi Jews and the existence of two additional rare inherited lysosomal glycolipid storage diseases, Tay Sachs and Nieman Pick, at a higher prevalence within the same ethnic group is believed to be caused by selective advantage.\n\nAvailable genetic data are consistent with a founder effect(4) whereas the nature of such an advantage has not been identified.\n\nThe aim of this study was to investigate the anti-HCV immune response in patients with GD in an attempt to define the potential role of high levels of GC in the immune system and antiviral immunity.\n\nStudy importance:\n\nThe host metabolic background exerts a profound effect on antiviral immunity, which may influence the clinical course of chronic HCV infection.\n\nThe accumulation of GC in patients with GD may provide a selective evolutionary advantage to these patients.\n\nGlucocerebroside was recently tested in human trials and shown to be effective in altering NKT- dependent metabolic pathways, insulin resistance, and associated liver injury.\n\nThe present study examine the capability of Glucocerebroside to be be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells.\n\nStatistical Analysis:\n\nData are presented as the mean ± standard deviation (SD). The Kruskal Wallis non-parametric ANOVA test was used to identify differences between the study groups.\n\nThe student t-test and non-parametric Mann-Whitney test were used to compare quantitative variables between the study groups as appropriate; P \\<0.05 was considered to be significant.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '90 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': "Patients with Gaucher Disease were recruited from the Sha'are Zedek Gaucher disease clinic, a national referral center for the disease.", 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with Gaucher disease\n* Patients with hepatitis C without Gaucher disease\n* Individuals or patients without Gaucher disease and hepatitis C\n* Individuals or patients who signed an approval for the research\n* Men and women 18\\< years of age , pregnant women\n\nExclusion Criteria:\n\n* Inabillity to give an approval for the research\n* Acute liver disease that can alter the lab results , such as: Rt. congestive heart failure\n\nsevere infection ,inflammation, medication such as : Statins , Isoniazid ,\n\nAmiodarone\n\n\\- Patients who received treatment for hepatitis C such as: Interferon ,\n\nPegylated interferon , Ribavirin\n\n\\-'}, 'identificationModule': {'nctId': 'NCT01274208', 'briefTitle': 'Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C', 'organization': {'class': 'OTHER', 'fullName': 'Shaare Zedek Medical Center'}, 'officialTitle': 'Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?', 'orgStudyIdInfo': {'id': 'SZMC- 89/10'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Gaucher Disease with Hepatitis C'}]}, 'contactsLocationsModule': {'locations': [{'zip': '91120', 'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Melamud', 'role': 'CONTACT', 'email': 'dr.bernardo@gmail.com'}, {'name': 'zimran, Prof.', 'role': 'CONTACT', 'email': 'azimran@gmail.com'}, {'name': 'Bernardo Melamud, Dr.', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Ari Zimran, Prof.', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Shaare Zedek , Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'city': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Yaron Ilan, Prof.', 'role': 'CONTACT', 'email': 'ilan@hadassah.org.il', 'phone': '972 2 6778231'}, {'name': 'Yaron Ilan, Prof.', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Hadassah Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}], 'centralContacts': [{'name': 'Bernardo Melamud, Dr.', 'role': 'CONTACT', 'email': 'dr.bernardo@gmail.com', 'phone': '972-508685845'}, {'name': 'Ari Zimran, Prof.', 'role': 'CONTACT', 'email': 'azimran@gmail.com', 'phone': '972-2-65555143'}], 'overallOfficials': [{'name': 'Bernardo Melamud, Dr.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Gaucher Clinic , Shaare zedek Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Shaare Zedek Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof. Ari Zimran', 'investigatorFullName': 'Ari Zimran', 'investigatorAffiliation': 'Shaare Zedek Medical Center'}}}}